- Home
- CINT vs DNTH Comparison
CINT vs DNTH Comparison
Compare CINT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- DNTH
- Stock Information
- Founded
- CINT 1995
- DNTH 2015
- Country
- CINT Brazil
- DNTH United States
- Employees
- CINT N/A
- DNTH 78
- Industry
- CINT EDP Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- DNTH Health Care
- Exchange
- CINT Nasdaq
- DNTH Nasdaq
- Market Cap
- CINT 803.4M
- DNTH 780.2M
- IPO Year
- CINT 2021
- DNTH N/A
- Fundamental
- Price
- CINT $5.46
- DNTH $23.57
- Analyst Decision
- CINT Buy
- DNTH Strong Buy
- Analyst Count
- CINT 6
- DNTH 8
- Target Price
- CINT $7.35
- DNTH $54.00
- AVG Volume (30 Days)
- CINT 124.6K
- DNTH 371.9K
- Earning Date
- CINT 08-13-2025
- DNTH 08-07-2025
- Dividend Yield
- CINT N/A
- DNTH N/A
- EPS Growth
- CINT 34.66
- DNTH N/A
- EPS
- CINT 0.25
- DNTH N/A
- Revenue
- CINT $452,826,000.00
- DNTH $4,854,000.00
- Revenue This Year
- CINT $11.21
- DNTH N/A
- Revenue Next Year
- CINT $13.48
- DNTH N/A
- P/E Ratio
- CINT $22.26
- DNTH N/A
- Revenue Growth
- CINT 1.02
- DNTH 17.87
- 52 Week Low
- CINT $4.42
- DNTH $13.37
- 52 Week High
- CINT $8.00
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- CINT 54.91
- DNTH 58.94
- Support Level
- CINT $5.15
- DNTH $23.24
- Resistance Level
- CINT $5.55
- DNTH $25.41
- Average True Range (ATR)
- CINT 0.26
- DNTH 1.54
- MACD
- CINT 0.05
- DNTH 0.24
- Stochastic Oscillator
- CINT 71.43
- DNTH 71.29
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.